Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| "(LUMINOUS)Study to observe the effectiveness andsafety of ranibizumab through individualized patienttreatment and associated " | Novartis | Completed | Ranibizumab 10mg/ml (Lucentis) | 4 | RFB002A2406 | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), Prince Sultan Military Medical City (Riyadh) |
| An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS) | Novartis | Completed | Fingolimod | 4 | CFTY720D-MAX-TH-01 | King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah) |
| An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE). | Novartis | Completed | Zoledronic acid | 4 | CZOL446H-MAX-SA-01 | King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh) |
| A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care | Kaleido Biosciences | Ongoing | KB195 | 2 | K020-218 | King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh) |
| A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy. | Roche | Terminated | RO7034067 | 2 | BP39056 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Roche | Terminated | Ocrelizumab | 3b | MN39159 | King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh) |
| A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS | Roche | Ongoing | Emicizumab | 3 | MO39129 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "Tranexamic acid for the treatment of gastrointestinal hemorrhage: aninternational randomized, double-blind, placebo-controlled trial" | Prince Mohammad Bin Abdulaziz Hospital | Completed | Tranexamic acid | 3 | ISRCTN11225767 | Prince Mohammad bin Abdulaziz hospital (Riyadh), King Fahad Medical City (Riyadh) |
| Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition. | Saudi Ajal | Completed | DICLOFENAC POTASSIUM | BE | 42856 | Saudi Ajal |
| A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial | Celgene | Completed | Luspatercept (ACE 536) | 3 | ACE-536-B-THAL-001 | King Khalid University Hospital (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.